[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-359814-105":59,"doc-detail-359814-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","redefining-m1-a-novel-three-tiered-classification-stratifies-prognosis-in-metastatic-breast-cancer","Redefining M1: a novel three-tiered classification stratifies prognosis in metastatic breast cancer","","Breast cancer distant metastases are currently staged under a single binary M1 category despite marked heterogeneity in metastatic burden, anatomic distribution, and brain metastasis status. A multi-center retrospective cohort of 2,615 metastatic breast cancer patients (2005–2020) was used to develop and validate a refined M-stage system incorporating these dimensions. Three groups (M1a oligometastasis, M1b with treatable brain metastases, M1c extensive/untreatable brain disease) showed clear overall survival gradients and improved prognostic discrimination over the traditional AJCC M1 stage.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/redefining-m1-a-novel-three-tiered-classification-stratifies-prognosis-in-metastatic-breast-cancer/359814/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/redefining-m1-a-novel-three-tiered-classification-stratifies-prognosis-in-metastatic-breast-cancer/359814.png","ImageObject",300,407,{"name":92,"@type":93},"Angel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-10","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is the traditional AJCC M1 staging insufficient for metastatic breast cancer prognosis?","Question",{"text":113,"@type":114},"It assigns all distant metastases to a single M1 category, failing to reflect heterogeneity in metastatic burden, tumor biology, metastatic distribution, and clinical outcomes.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does the proposed three-tiered M-stage classification define M1a, M1b, and M1c?",{"text":118,"@type":114},"M1a is oligometastasis with 1–5 lesions, ≤2 organs, and no brain metastases; M1b is oligometastasis with 1–5 lesions, ≤2 organs, including 1–3 treatable brain metastases; M1c includes >5 lesions, ≥3 organs, or untreatable brain metastases.",{"name":120,"@type":111,"acceptedAnswer":121},"What evidence shows the new classification improves prognostic stratification compared with the traditional binary M1 stage?",{"text":122,"@type":114},"The system demonstrated distinct overall survival medians across groups and higher prognostic discrimination (C-index 0.67 vs 0.59) while reclassifying 41.7% of patients into more precise risk categories.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},359814,1790184128,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},687207412472,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Liu et al. BMC Cancer (2026) 26:534 BMC Cancer  \n[https://doi.org/10.1186/s12885-026-15861-2](https://doi.org/10.1186/s12885-026-15861-2)  \nRESEARCH Open Access  \nRedefining M1: a novel three-tiered classification stratifies prognosis in metastatic breast cancer  \nShanqing Liu1, Yong Li1, Yan Shen1, Qixin Mao 1 and Lianfang Li 1*  \nAbstract  \nBackground The current AJCC staging system for breast cancer categorizes all distant metastases under a monolithic M1 designation, failing to capture profound heterogeneity in outcomes. This study aimed to develop and validate a refined M-stage classification that integrates metastatic burden, anatomic site, and brain metastasis status to improve prognostic stratification.  \nMethods In this multi-center, retrospective study, 2,615 patients with metastatic breast cancer (diagnosed 2005–2020) were classified into three proposed categories: M1a (Oligometastasis: 1–5 lesions, ≤ 2 organs, no brain metastases), M1b (Oligometastasis: 1–5 lesions, ≤ 2 organs, includes 1–3 treatable brain metastases), and M1c (Extensive Metastasis: > 5 lesions, ≥ 3 organs, or untreatable brain metastases) . Overall survival (OS) was compared using Kaplan–Meier curves and Cox proportional hazards models. Prognostic performance was assessed using Harrell’s C-index and compared to the traditional binary M1 stage.  \nResults The cohort was stratified into M1a (n = 672, 25 . 7%), M1b (n = 418, 16. 0%), and M1c (n = 1,525, 58 . 3%) . A clear prognostic gradient was observed: median OS was 98.3 months for M1a, 62.1 months for M1b, and 32.7 months for M1c (log-rank p \u003C 0. 001) . The proposed classification was an independent prognostic factor on multivariable analysis (M1a vs. M1c adjusted HR = 0 .49, p \u003C 0. 001) . It demonstrated superior prognostic discrimination compared to the traditional M1 stage (C-index 0.67 vs. 0. 59, Δ = 0 . 08, p \u003C 0. 001), reclassifying 41. 7% of patients into more precise risk categories.  \nConclusion This novel three-tiered M-stage classification robustly stratifies metastatic breast cancer into prognostically distinct groups, outperforming the current binary system. It provides a practical framework for refining prognostication, personalizing therapy, and enriching future clinical trials.  \nKeywords Metastatic breast cancer, Oligometastasis, Staging, Prognostic classification, Overall Survival  \n*Correspondence: Lianfang Li  \n[zlyylilianfang1700@zzu.edu.cn](zlyylilianfang1700@zzu.edu.cn); [drxiao0309@126.com](drxiao0309@126.com)  \n1Department of Breast, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou  \n450008, People’s Republic of China  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nLiu et al. BMC Cancer (2026) 26:534  \nIntroduction  \nMetastatic breast cancer (MBC) has traditionally been viewed as a systemic, incurable disease, with treatment goals centered on palliation ","cbCaieWk1XkvZTMd","https://ap.wps.com/l/cbCaieWk1XkvZTMd","pdf",2417379,11,"English","# Introduction\n## Background and rationale for refined M1 staging\n## Oligometastasis concept and prior evidence\n## Limitations of existing staging and emerging trials\n# Methods\n## Study design and patient cohort\n## Proposed three-tiered M-stage definitions\n## Statistical analyses and prognostic evaluation\n# Results\n## Patient distribution across M1a, M1b, M1c\n## Overall survival gradients\n## Multivariable validation and performance vs traditional M1\n# Conclusion\n## Clinical implications for prognosis and therapy personalization","[{\"question\":\"Why is the traditional AJCC M1 staging insufficient for metastatic breast cancer prognosis?\",\"answer\":\"It assigns all distant metastases to a single M1 category, failing to reflect heterogeneity in metastatic burden, tumor biology, metastatic distribution, and clinical outcomes.\"},{\"question\":\"How does the proposed three-tiered M-stage classification define M1a, M1b, and M1c?\",\"answer\":\"M1a is oligometastasis with 1–5 lesions, ≤2 organs, and no brain metastases; M1b is oligometastasis with 1–5 lesions, ≤2 organs, including 1–3 treatable brain metastases; M1c includes \\u003e5 lesions, ≥3 organs, or untreatable brain metastases.\"},{\"question\":\"What evidence shows the new classification improves prognostic stratification compared with the traditional binary M1 stage?\",\"answer\":\"The system demonstrated distinct overall survival medians across groups and higher prognostic discrimination (C-index 0.67 vs 0.59) while reclassifying 41.7% of patients into more precise risk categories.\"}]","Redefining M1: a novel three-tiered classification stratifies prognosis in metastatic breast cancer | PDF",1790137903,28,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6e2082286e67d8a4c6bd4f2011724d94.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7888a42de76b168700960243b2c63166.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1567eb6151e650fbc5592eee558c3c8d.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/983e472383b3680208b097de1de60023.webp",980,1306]